■ABO血型不合(ABOi)的肾移植在取得成功的结果方面提出了重大挑战。本研究旨在探讨各种干预措施和技术对提高ABOi肾移植成功率的影响。
■我们对2012年11月至2023年3月接受ABOi肾移植的患者进行了回顾性观察分析。该研究共纳入105名患者。我们收集并分析了患者的人口统计数据,术前评估,手术细节,和术后结果。
■捐赠者和接受者的平均年龄分别为50.52±10.32和36.63±11.61岁,分别。大多数接受者是男性(81.9%),而大多数捐献者是女性(89.5%)。受者中最常见的血型是O(69.5%),在捐赠者中,是B(46.7%)。慢性肾脏病和透析的中位持续时间为12个月(四分位距[IQR],7-28个月)和6个月(IQR,2-12个月),分别。基线抗体滴度(抗A和抗B)范围为64.0至256.0,而在手术当天,他们是≤8。围手术期并发症包括低血压(10.5%),急性肾小管坏死(5.7%),移植物功能延迟(3.8%),血肿再探查(3.8%)。
■ABOi肾移植是缺乏ABO匹配可用供体的受体的可行选择。围手术期关注,包括低蛋白血症,感染的风险增加,凝血功能障碍,无菌预防措施,和免疫监测,必须小心处理。
UNASSIGNED: ABO-incompatible (ABOi) kidney transplantation poses significant challenges in achieving successful outcomes. This study aimed to investigate the impact of various interventions and techniques on improving the success rates of ABOi kidney transplantation.
UNASSIGNED: We conducted a retrospective observational analysis of patients who underwent ABOi kidney transplantation from November 2012 to March 2023. The study included a total of 105 patients. We collected and analyzed data on patient demographics, preoperative assessments, surgical details, and postoperative outcomes.
UNASSIGNED: The mean ages of the donors and recipients were 50.52±10.32 and 36.63±11.61 years, respectively. The majority of recipients were male (81.9%), while most donors were female (89.5%). The most common blood group among recipients was O (69.5%), and among donors, it was B (46.7%). The median durations of chronic kidney disease and dialysis were 12 months (interquartile range [IQR], 7-28 months) and 6 months (IQR, 2-12 months), respectively. Baseline antibody titers (anti-A and anti-B) ranged from 64.0 to 256.0, while on the day of surgery, they were ≤8. Perioperative complications included hypotension (10.5%), acute tubular necrosis (5.7%), delayed graft function (3.8%), and reexploration (3.8%) due to hematoma.
UNASSIGNED: ABOi kidney transplantation is a viable option for recipients lacking available donors with an ABO-compatible match. Perioperative concerns, including hypoalbuminemia, heightened risk of infections, coagulopathies, aseptic precautions, and immunological surveillance, must be carefully addressed.